ATIC is supporting a new clinical trial based in Queensland called the ASITI-201 trial. Led by ATIC Steering Committee member Professor Ranjeny Thomas, this phase 1 trial will test a new immune-modifying treatment (ASITI-201) for type 1 diabetes.

ASITI-201 is made of small lipid particles containing proteins combined with a form of vitamin D, designed to slow down or stop the immune attack responsible for destroying insulin-producing beta cells in the pancreas.

The aim of this trial is to assess the safety, dosing and immune effects of ASITI-201 in humans. ASITI-201 has now commenced recruitment and at this stage is only available to people living in Queensland.

View ASITI-201 flyer